A217330 Stock Overview
A biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cytogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,180.00 |
| 52 Week High | ₩16,700.00 |
| 52 Week Low | ₩6,370.00 |
| Beta | 0.39 |
| 11 Month Change | 4.51% |
| 3 Month Change | -24.42% |
| 1 Year Change | -52.45% |
| 33 Year Change | -66.76% |
| 5 Year Change | 118.68% |
| Change since IPO | 38.08% |
Recent News & Updates
Shareholder Returns
| A217330 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.3% | 4.0% | 0.9% |
| 1Y | -52.5% | 49.5% | 3.8% |
Return vs Industry: A217330 underperformed the KR Biotechs industry which returned 49.5% over the past year.
Return vs Market: A217330 underperformed the KR Market which returned 3.8% over the past year.
Price Volatility
| A217330 volatility | |
|---|---|
| A217330 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A217330 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A217330's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 56 | Byung-Hee Jeon | www.cytogenlab.com |
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name.
Cytogen, Inc. Fundamentals Summary
| A217330 fundamental statistics | |
|---|---|
| Market cap | ₩165.64b |
| Earnings (TTM) | -₩15.87b |
| Revenue (TTM) | ₩3.55b |
46.6x
P/S Ratio-10.4x
P/E RatioIs A217330 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A217330 income statement (TTM) | |
|---|---|
| Revenue | ₩3.55b |
| Cost of Revenue | ₩3.00b |
| Gross Profit | ₩555.22m |
| Other Expenses | ₩16.43b |
| Earnings | -₩15.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -688.04 |
| Gross Margin | 15.62% |
| Net Profit Margin | -446.65% |
| Debt/Equity Ratio | 23.1% |
How did A217330 perform over the long term?
See historical performance and comparison